Lansoprazol Basi

Lansoprazole, the active ingredient in Lansoprazol Basi, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related disorders such as gastro‑esophageal reflux disease, peptic ulcer disease and ulcer prevention in patients taking non‑steroidal anti‑inflammatory drugs.

GNH USA supplies Lansoprazol Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and healthcare institutions worldwide, with a focus on quality assurance and regulatory compliance.

Lansoprazole is used to treat conditions related to excess gastric acid production. - Gastro‑esophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation. - Peptic ulcer disease: promotes ulcer healing by maintaining a higher gastric pH. - NSAID‑induced ulcer prophylaxis: prevents ulcer formation in patients receiving chronic NSAID therapy. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by suppressing acid.

Lansoprazole may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema) - Clostridioides difficile infection - Elevated liver enzymes - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Acute interstitial nephritis - Hypomagnesemia (low magnesium levels)

When prescribing Lansoprazole, several precautionary measures should be considered to ensure safe use. - Renal function assessment: adjust use in patients with severe renal impairment. - Magnesium monitoring: periodic checks recommended for long‑term therapy. - Hepatic impairment: use with caution in patients with liver disease. - Discontinuation strategy: taper or monitor for rebound acid hypersecretion after stopping. - Drug interactions: review concomitant medications that may affect acid levels or drug metabolism. - Store at room temperature: keep in the original container, protect from moisture and light.

Lansoprazole can affect the pharmacokinetics of several medicines, requiring attention to avoid clinically relevant interactions.

Major Interactions (Avoid): - Rilpivirine: reduced absorption; avoid co‑administration. - Atazanavir: decreased plasma concentrations; avoid use together. - Ketoconazole: requires separate dosing; avoid simultaneous intake.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation. - Digoxin: increased serum levels; check concentrations. - Methotrexate: reduced clearance; monitor for toxicity.